CVS Health
CVS
$95.38
-0.72%
CVS Health Corporation is a diversified healthcare services company operating through retail pharmacies, pharmacy benefit management (PBM), and health insurance (Aetna), serving millions of customers and members across the United States. As one of the largest integrated healthcare providers, CVS combines a retail footprint of approximately 9,000 stores with a top-tier PBM processing about 2 billion claims annually and an insurer covering roughly 26 million medical members, positioning it as a unique platform in the evolving healthcare landscape. The current investor narrative centers on a potential turnaround, driven by a stronger-than-expected Q1 2026 earnings beat, a rebound in its insurance segment's medical cost ratio, and a favorable Medicare payment decision that added $13 billion in revenue visibility, fueling a 24% rally since May and raising questions about the sustainability of this momentum.…
CVS
CVS Health
$95.38
Related headlines
Investment Opinion: Should I buy CVS Today?
Rating: Buy. CVS is a compelling value turnaround play with strong momentum, as evidenced by a 24% rally since May and a consensus Strong Buy rating. The average analyst target of $116.04 implies 20% upside, and the forward PE of 11.36x is a 38.6% discount to the industry average of 18.5x. The company's revenue growth is accelerating (6.17% YoY), and free cash flow is robust at $7.39 billion TTM, supporting dividend payments and debt reduction.
Sign up to view all
CVS 12-Month Price Forecast
The AI assessment is bullish on CVS over the next 12 months, driven by a compelling valuation, improving operational metrics, and a favorable regulatory environment. The forward PE of 11.36x is significantly below peers, suggesting the market is not fully pricing in the earnings recovery. However, confidence is medium due to the high trailing PE and potential for medical cost volatility. The stance would be upgraded to high confidence if the company delivers another strong quarter with EPS above $2.50 and maintains revenue growth above 6%. Conversely, a downgrade to neutral would occur if medical costs rise or revenue growth decelerates below 4%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS Health's 12-month outlook, with a consensus price target around $116.04 and implied upside of +21.7% versus the current price.
Average Target
$116.04
0 analysts
Implied Upside
+21.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $148
Analyst target range
The target price range spans from a low of $103.00 to a high of $148.00, indicating a wide spread of 43.7% between the most bearish and bullish scenarios. The low target of $103.00 still represents a 6.5% upside, suggesting even the most conservative analysts see limited downside, while the high target of $148.00 implies a 53% upside, likely assuming successful execution of cost synergies, continued medical cost ratio improvement, and potential multiple expansion. Recent ratings from major firms like Wells Fargo, RBC Capital, and Morgan Stanley have all been reaffirmed as Overweight/Outperform, with no downgrades in the past three months, signaling consistent positive sentiment. The wide range reflects uncertainty around healthcare policy and competitive dynamics, but the overall bullish consensus and recent price momentum suggest analysts are increasingly confident in CVS's recovery.
Drowning in data?
Find the real signal!
Bulls vs Bears: CVS Investment Factors
CVS presents a compelling turnaround story with strong Q1 2026 earnings, accelerating revenue growth, and a favorable regulatory environment. The bull case is supported by a forward PE of 11.36x, well below the industry average, and a consensus Strong Buy rating with 20% upside to the average target. However, bears point to the high trailing PE, persistent margin pressure, and elevated debt levels, which could weigh on the stock if the recovery falters. The most critical tension is whether the earnings recovery is sustainable—if the medical cost ratio remains low and revenue growth continues, the stock could re-rate higher; if not, the current valuation may prove too optimistic. Overall, the evidence currently favors the bull case, given the strong operational momentum and analyst confidence.
Bullish
- Strong Q1 2026 earnings beat: Q1 2026 EPS of $2.31 significantly exceeded the prior year's $1.41, driven by a lower medical cost ratio and improved operational efficiency. This beat led to raised full-year guidance and a 24% stock rally since May, signaling a potential sustainable turnaround.
- Favorable Medicare payment decision: A CMS decision added $13 billion in revenue visibility for 2027, boosting the insurance segment's outlook. This regulatory tailwind reduces uncertainty and supports the company's forward earnings recovery, a key driver of the recent rally.
- Revenue growth accelerating: Revenue grew 6.17% YoY in Q1 2026 to $100.43 billion, up from 3.5% growth in Q2 2025. The acceleration is driven by pharmacy revenue ($56.94B) and premiums ($33.79B), indicating positive momentum across core segments.
- Attractive forward valuation: With a forward PE of 11.36x versus the industry average of 18.5x, CVS trades at a 38.6% discount to peers. This implies the market is pricing in a significant earnings recovery, offering upside if the turnaround materializes.
Bearish
- High trailing PE of 56.7x: The trailing PE of 56.7x is elevated due to depressed trailing earnings (net margin of only 0.44%). If the expected earnings recovery stalls, the stock could face de-rating, as the current price already reflects optimistic forward assumptions.
- Gross margin pressure persists: Gross margin declined from 15.22% in Q1 2025 to 15.56% in Q1 2026, but remains below historical levels. Reimbursement challenges and mix shifts in retail pharmacy continue to compress margins, limiting profit growth.
- High debt burden: Debt-to-equity stands at 1.24, and interest expense was $774 million in Q1 2026. The company's leverage increases financial risk, especially if cash flows weaken or interest rates remain elevated.
- Recent price pullback: The stock has fallen 2.4% over the past month and 12.6% from its 52-week high of $110.68, indicating profit-taking after the sharp rally. This suggests momentum may be fading, and the stock could consolidate.
CVS Technical Analysis
CVS has been in a robust uptrend over the past year, with the stock price appreciating 31.28% over the last 12 months, significantly outperforming the S&P 500's 18.65% gain. The current price of $96.74 sits at 87.4% of the 52-week range (between $69.51 low and $110.68 high), indicating the stock is trading near its highs, which typically reflects strong momentum but also potential overextension. The stock's beta of 0.58 suggests it is less volatile than the broader market, providing some cushion in turbulent times, yet the proximity to the 52-week high of $110.68 (about 12.6% above current levels) highlights a key resistance zone.
Beta
0.58
0.58x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$70-$111
Price range past year
Annual Return
+32.9%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | -0.3% | -1.4% |
| 3m | -5.1% | +3.3% |
| 6m | +25.3% | +15.1% |
| 1y | +32.9% | +17.2% |
| ytd | +19.0% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
CVS's revenue trajectory has been solidly growing, with Q1 2026 revenue reaching $100.43 billion, up 6.17% year-over-year from $94.59 billion in Q1 2025. This growth is driven by strength in pharmacy revenue ($56.94 billion) and premiums ($33.79 billion), though the company's gross margin has been under pressure, declining from 15.22% in Q1 2025 to 15.56% in Q1 2026, reflecting ongoing reimbursement and mix challenges. The multi-quarter trend shows revenue growth accelerating from 3.5% in Q2 2025 to 6.2% in Q1 2026, indicating a positive inflection, but the sustainability of this growth is tied to the insurance segment's medical cost management and retail pharmacy competition.
Quarterly Revenue
$100.4B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
15.6%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Given that CVS is profitable with a trailing twelve-month net income of $2.94 billion, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 56.69x, while the forward PE is 11.36x, a massive gap that implies the market expects a dramatic earnings recovery, likely driven by the recent operational improvements and favorable Medicare rate adjustments. This forward multiple is significantly lower than the industry average PE of 18.5x (based on available sector data), suggesting CVS trades at a 38.6% discount to its peers, which may be justified by its historical margin volatility and regulatory exposure but also presents a potential value opportunity if the turnaround materializes.
PE
56.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. CVS carries a high debt-to-equity ratio of 1.24, with quarterly interest expenses of $774 million, which could strain cash flows if earnings disappoint. The company's gross margin is thin at 15.56% and has been volatile, reflecting reimbursement pressures and mix shifts. Additionally, the trailing net margin is just 0.44%, indicating that profitability is highly sensitive to medical cost trends and operational execution. A failure to sustain the lower medical cost ratio could quickly erode earnings, as seen in Q3 2025 when the company posted a net loss of $3.97 billion due to elevated costs.
FAQ
The key risks include: 1) Financial risk from high debt (debt-to-equity of 1.24) and thin margins, which could strain cash flows if earnings disappoint. 2) Competitive risk from Amazon and other pharmacy players, which could pressure market share. 3) Regulatory risk from changes to Medicare Advantage rates or drug pricing policies, which could impact the insurance and PBM segments. 4) Execution risk in the turnaround, particularly in managing medical costs. The most severe risk is a resurgence in medical costs, which could lead to a 28% downside to the 52-week low of $69.51.
The 12-month forecast is bullish, with a base case target of $100-116 (50% probability), a bull case of $110-130 (30% probability), and a bear case of $80-95 (20% probability). The most likely scenario is the base case, where CVS delivers steady earnings growth and the stock reaches the analyst average target of $116.04. The key assumption is that the medical cost ratio remains stable and revenue growth continues at 5-6%. If these hold, the stock could see 20% upside from current levels.
CVS is undervalued on a forward basis, with a forward PE of 11.36x versus the industry average of 18.5x, implying a 38.6% discount. However, the trailing PE of 56.7x is elevated due to depressed trailing earnings, reflecting the market's expectation of a significant recovery. The market is pricing in a sharp earnings rebound, which is supported by recent operational improvements. If the recovery stalls, the stock could be considered overvalued, but current fundamentals suggest it is undervalued relative to its growth potential.
CVS is a good buy for investors seeking a value turnaround play with a favorable risk/reward. The stock trades at a forward PE of 11.36x, a 38.6% discount to the industry average, and analysts see 20% upside to the average target of $116.04. The main risk is that the earnings recovery may not materialize as expected, which could lead to a de-rating. However, with strong Q1 2026 earnings and a favorable Medicare decision, the odds favor the bull case. For long-term investors with a 12-month horizon, CVS offers an attractive entry point, but it is not without volatility.
CVS is better suited for long-term investment, given its turnaround nature and the time needed for the earnings recovery to fully materialize. The stock's beta of 0.58 indicates lower volatility than the market, making it less attractive for short-term traders seeking quick gains. The company pays a dividend yield of 3.38%, providing income while waiting for capital appreciation. A minimum holding period of 12-18 months is recommended to allow the turnaround to play out and for the market to re-rate the stock. Short-term traders may find opportunities around earnings announcements, but the stock's recent volatility suggests caution.
